Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER

Por Sun, Z., Prat, A., Cheang, M.C.U., Gelber, R.D., Perou, C.M.
Publicado no Ann Oncol (2015)

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

Por Prat, A., Parker, J. S., Fan, C., Cheang, M. C. U., Miller, L. D., Bergh, J., Chia, S. K. L., Bernard, P. S., Nielsen, T. O., Ellis, M. J., Carey, L. A., Perou, C. M.
Publicado em 2012

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial

Por Sipos, O., Tovey, H., Quist, J., Haider, S., Nowinski, S., Gazinska, P., Kernaghan, S., Toms, C., Maguire, S., Orr, N., Linn, S.C., Owen, J., Gillett, C., Pinder, S.E., Bliss, J.M., Tutt, A., Cheang, M.C.U., Grigoriadis, A.
Publicado no Ann Oncol (2021)

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

Por Cheang, M. C. U., Bliss, J. M., Viale, G., Speirs, V., Palmieri, C., Shaaban, A., Lønning, P. E., Morden, J., Porta, N., Jassem, J., van De Velde, C. J., Rasmussen, B. B., Verhoeven, D., Bartlett, J. M. S., Coombes, R. C.
Publicado no Breast Cancer Res Treat (2017)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Por Prat, A, Lluch, A, Albanell, J, Barry, W T, Fan, C, Chacón, J I, Parker, J S, Calvo, L, Plazaola, A, Arcusa, A, Seguí-Palmer, M A, Burgues, O, Ribelles, N, Rodriguez-Lescure, A, Guerrero, A, Ruiz-Borrego, M, Munarriz, B, López, J A, Adamo, B, Cheang, M C U, Li, Y, Hu, Z, Gulley, M L, Vidal, M J, Pitcher, B N, Liu, M C, Citron, M L, Ellis, M J, Mardis, E, Vickery, T, Hudis, C A, Winer, E P, Carey, L A, Caballero, R, Carrasco, E, Martín, M, Perou, C M, Alba, E
Publicado em 2014